[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589501":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":28,"locations":28,"responsibleParty":29,"collaborators":28,"id":31,"slug":28,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":32,"sex":38,"minAge":39,"maxAge":28,"enrollmentInfo":40,"targetDuration":28,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":28,"overallStatus":49,"whyStopped":28,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":28},{"fullName":5,"class":6},"Azienda di Servizi alla Persona di Pavia","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Berbevis 500 mg\u002Fdie","EXPERIMENTAL","Berbevis™, 250 mg x 2\u002Fday, 1 tablet in the morning and 1 in the evening.",[13],"Dietary Supplement: Berbevis supplement",{"label":15,"type":10,"description":16,"interventionNames":17},"Berbevis 750 mg\u002Fdie","Berbevis™, 250 mg x 3\u002Fday, 2 tablets in the morning and 1 in the evening.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Berbevis 1000 mg\u002Fdie","Berbevis™, 250 mg x 4\u002Fday, 2 tablets in the morning and 2 in the evening.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DIETARY_SUPPLEMENT","Berbevis supplement","This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.",[19,9,15],null,{"type":30,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100589501",false,"NCT06955234","Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose","Berbevis Project: Multitarget Dose-finding Study","BERBEVIS-DFG-0","Inclusion Criteria:\n\n* fasting blood glucose between 100 and 126 mg\u002Fdl\n* BMI between 25 and 35 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Fasting blood glucose below 100 mg\u002Fdl\n* BMI \\\u003C 25 or \\> 35 kg\u002Fm\\^2","ALL","18 Years",{"count":41,"type":42},90,"ESTIMATED","INTERVENTIONAL",[45],"NA","Assessing the effects of a nutraceutical supplement (Berbevis™) in adults with impaired fasting glucose (100-126 mg\u002FdL) and BMI between 25 and 35. Ninety participants will be assigned to three parallel groups receiving Berbevis™ at increasing daily doses (500 mg, 750 mg, and 1000 mg) for 2 months.",[48],"Impaired Fasting Glucose (IFG)","NOT_YET_RECRUITING","2025-11-23",{"date":52,"type":53},"2025-11-25","ACTUAL",{"date":55,"type":42},"2026-06-15",{"date":57,"type":42},"2026-09-15",{"name":5,"class":6}]